feed,title,long_url,short_url
SeekingAlpha,Longeveron meets primary efficacy endpoint in mid-stage trial for aging frailty,https://seekingalpha.com/news/3730216,
SeekingAlpha,CareMax reports Q2 results,https://seekingalpha.com/news/3730215,
SeekingAlpha,Ipsen withdraws palovarotene NDA following FDA discussions,https://seekingalpha.com/news/3730214,
